Yeast-produced RBD-based recombinant protein vaccines elicit broadly neutralizing antibodies and durable protective immunity against SARS-CoV-2 infection

Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections

(2021) Chao Zhang et al.   Nature Communications

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice

(2021) Jing-Hui Tian et al.   Nature Communications

Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies

(2021) Jie Hu et al.   Cellular & Molecular Immunology

Emergence of a SARS-CoV-2 variant of concern with mutations in spike glycoprotein

(2021) Houriiyah Tegally et al.   NATURE

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7

(2021) Pengfei Wang et al.   NATURE

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

(2021) Constantinos Kurt Wibmer et al.   NATURE MEDICINE

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera

(2021) Alexander Muik et al.   SCIENCE

Structural and Functional Characterization of SARS-CoV-2 RBD Domains Produced in Mammalian Cells

(2021) Christoph Gstöttner et al.   ANALYTICAL CHEMISTRY

Process development and scale-up optimization of the SARS-CoV-2 receptor binding domain–based vaccine candidate, RBD219-N1C1

(2021) Jungsoon Lee et al.   APPLIED MICROBIOLOGY AND BIOTECHNOLOGY

Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant

(2021) Carl Graham et al.   IMMUNITY

A novel coronavirus outbreak of global health concern

(2020) Chen Wang et al.   LANCET

A pneumonia outbreak associated with a new coronavirus of probable bat origin

(2020) Peng Zhou et al.   NATURE

A Novel Coronavirus from Patients with Pneumonia in China, 2019

(2020) Na Zhu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia

(2020) Qun Li et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

(2020) Jasper Fuk-Woo Chan et al.   Emerging Microbes & Infections

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

(2020) Qihui Wang et al.   CELL

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

(2020) Alexandra C. Walls et al.   CELL

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

(2020) Markus Hoffmann et al.   CELL

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine

(2020) Wanbo Tai et al.   Cellular & Molecular Immunology

A human neutralizing antibody targets the receptor binding site of SARS-CoV-2

(2020) Rui Shi et al.   NATURE

Cell entry mechanisms of SARS-CoV-2

(2020) Jian Shang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS

(2020) Lianpan Dai et al.   CELL

A Thermostable mRNA Vaccine against COVID-19

(2020) Na-Na Zhang et al.   CELL

A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity

(2020) Jingyun Yang et al.   NATURE

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

(2020) Kizzmekia S. Corbett et al.   NATURE

SARS-CoV-2 vaccines in development

(2020) Florian Krammer   NATURE

Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement

(2020) Jinkai Zang et al.   Cell Discovery

SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation

(2020) Katlyn Lederer et al.   IMMUNITY

Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice

(2020) Fatai S. Oladunni et al.   Nature Communications

Protoporphyrin IX and verteporfin potently inhibit SARS-CoV-2 infection in vitro and in a mouse model expressing human ACE2

(2020) Chenjian Gu et al.   Science Bulletin

Structural analysis of N-/O-glycans assembled on proteins in yeasts

(2018) Eun Jung Thak et al.   JOURNAL OF MICROBIOLOGY

Global site-specific analysis of glycoprotein N-glycan processing

(2018) Liwei Cao et al.   Nature Protocols

Prevention of cervical cancer: journey to develop the first human papillomavirus virus-like particle vaccine and the next generation vaccine

(2016) Janine T Bryan et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Bat-to-human: spike features determining ‘host jump’ of coronaviruses SARS-CoV, MERS-CoV, and beyond

(2015) Guangwen Lu et al.   TRENDS IN MICROBIOLOGY

Production of sialylated O-linked glycans in Pichia pastoris

(2013) S. R. Hamilton et al.   GLYCOBIOLOGY

Detection, characterization and quantitation of Coxsackievirus A16 using polyclonal antibodies against recombinant capsid subunit proteins

(2011) Qingwei Liu et al.   JOURNAL OF VIROLOGICAL METHODS